NGeneBio (A354200) Stock Overview
Develops in vitro diagnostics companion diagnostics products and bioinformatics software. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A354200 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
NGeneBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,040.00 |
| 52 Week High | ₩2,765.00 |
| 52 Week Low | ₩1,325.00 |
| Beta | 1.32 |
| 1 Month Change | -9.33% |
| 3 Month Change | 30.19% |
| 1 Year Change | 25.15% |
| 3 Year Change | -73.95% |
| 5 Year Change | -88.70% |
| Change since IPO | -92.05% |
Recent News & Updates
Shareholder Returns
| A354200 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.9% | 0.5% | 1.8% |
| 1Y | 25.2% | 31.6% | 108.1% |
Return vs Industry: A354200 underperformed the KR Biotechs industry which returned 31.6% over the past year.
Return vs Market: A354200 underperformed the KR Market which returned 108.1% over the past year.
Price Volatility
| A354200 volatility | |
|---|---|
| A354200 Average Weekly Movement | 16.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in KR Market | 15.4% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A354200's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A354200's weekly volatility has increased from 10% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 58 | Min-sik Kim | ngenebio.com/kr/ |
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing; and OncoaccuPanel, a solid tumor oncology next generation sequencing test. The company also provides NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS.
NGeneBio Co., Ltd. Fundamentals Summary
| A354200 fundamental statistics | |
|---|---|
| Market cap | ₩53.80b |
| Earnings (TTM) | -₩12.44b |
| Revenue (TTM) | ₩9.98b |
Is A354200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A354200 income statement (TTM) | |
|---|---|
| Revenue | ₩9.98b |
| Cost of Revenue | ₩8.04b |
| Gross Profit | ₩1.94b |
| Other Expenses | ₩14.38b |
| Earnings | -₩12.44b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -476.36 |
| Gross Margin | 19.46% |
| Net Profit Margin | -124.60% |
| Debt/Equity Ratio | 102.2% |
How did A354200 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/18 11:58 |
| End of Day Share Price | 2026/03/18 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NGeneBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.